RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SkinBioTherapeutics Stock

SkinBioTherapeutics P/E 2024

SkinBioTherapeutics P/E

-4.78

Ticker

SBTX.L

ISIN

GB00BF33H870

WKN

A2DPW8

As of Dec 4, 2024, SkinBioTherapeutics's P/E ratio was -4.78, a -47.76% change from the -9.15 P/E ratio recorded in the previous year.

The SkinBioTherapeutics P/E history

SkinBioTherapeutics Aktienanalyse

What does SkinBioTherapeutics do?

SkinBioTherapeutics PLC is an innovative biotechnology company specialized in the development of skincare products. The company was founded in 2016 in Manchester, United Kingdom, and has since been led by a team of experienced scientists and entrepreneurs. The company's CEO, Dr. Catherine O'Neill, founded SkinBioTherapeutics PLC with the goal of developing innovative skincare products based on the latest scientific findings. The company focuses on the development of products using probiotic bacteria, which have been found to influence the immune system. SkinBioTherapeutics PLC is divided into three divisions: skincare, medical applications, and cosmetics. The skincare division develops products specifically tailored to the needs of individuals with sensitive and problematic skin, aiming to improve the skin's immune system and reduce inflammation and irritation. The medical applications division focuses on the use of probiotic bacteria in treating skin conditions such as psoriasis, eczema, and acne. The cosmetics division, under the brand "SkinBiotix," develops products to improve skin health and appearance. Currently, SkinBioTherapeutics PLC offers several products, including SkinBiotix Balance, a skincare cream for sensitive and problematic skin, SkinBiotix Cleanse, a gentle water-based cleanser, and SkinBiotix Strengthen, a rich moisturizer for dry and problematic skin. With its unique technology platform and strong emphasis on research and development, SkinBioTherapeutics PLC is well-positioned to continue growing and bringing its innovative products to market. SkinBioTherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering SkinBioTherapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of SkinBioTherapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing SkinBioTherapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of SkinBioTherapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in SkinBioTherapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about SkinBioTherapeutics stock

What is the price-to-earnings ratio of SkinBioTherapeutics?

The price-earnings ratio of SkinBioTherapeutics is currently -4.78.

How has the price-earnings ratio of SkinBioTherapeutics changed compared to last year?

The price-to-earnings ratio of SkinBioTherapeutics has increased by -47.76% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of SkinBioTherapeutics high compared to other companies?

Yes, the price-to-earnings ratio of SkinBioTherapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of SkinBioTherapeutics affect the company?

An increase in the price-earnings ratio of SkinBioTherapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of SkinBioTherapeutics affect the company?

A decrease in the price-earnings ratio of SkinBioTherapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of SkinBioTherapeutics?

Some factors that influence the price-earnings ratio of SkinBioTherapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does SkinBioTherapeutics pay?

Over the past 12 months, SkinBioTherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SkinBioTherapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of SkinBioTherapeutics?

The current dividend yield of SkinBioTherapeutics is .

When does SkinBioTherapeutics pay dividends?

SkinBioTherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SkinBioTherapeutics?

SkinBioTherapeutics paid dividends every year for the past 0 years.

What is the dividend of SkinBioTherapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is SkinBioTherapeutics located?

SkinBioTherapeutics is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von SkinBioTherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SkinBioTherapeutics from 12/4/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did SkinBioTherapeutics pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of SkinBioTherapeutics in the year 2023?

In the year 2023, SkinBioTherapeutics distributed 0 GBP as dividends.

In which currency does SkinBioTherapeutics pay out the dividend?

The dividends of SkinBioTherapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SkinBioTherapeutics

Our stock analysis for SkinBioTherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SkinBioTherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.